-- NDA resubmission expected in Second Half of 2024, if successful-- --Oral sulopenem, if approved, could be the first antibiotic...
Recent in-vivo studies conducted in partnership with the University of Toronto confirm Formulation Candidate’s anti-seizure properties allowing for formalization of...
Company also presenting at upcoming investor conferencesWATERTOWN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...
Reduction of Approximately 20% in Organization Headcount Company Expects to Extend Cash Runway into Q3 2023 PolyPid Intends to Discuss...
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing...
Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapyHOOKIPA to receive...
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular...
AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared...
Agreements Showcase Company’s Ability to Support Novel Therapeutic Programs Regardless of Development Stage; Services Focused on Both Preclinical and Last...
Agreement will allow researchers to streamline development of on-demand and automated production of CRISPR-Cas9 guide RNASAN DIEGO, Oct. 19, 2022...
Further Demonstrating Possibilities for Systemic Delivery of Large MoleculesSAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq:...
Figure: 1 Compound F3 and enhanced activity derivative F3-8-60 directly bind to K-RAS Figure: 2 F3 class compounds block RAS...
SAN FRANCISCO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein...
HOUSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and...
PRINCETON, N.J. and NEW YORK and BENGALURU, India, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization...
Maravai LifeSciences and Recently-Appointed CEO Trey Martin Vigorously Defending Against SuitSAN DIEGO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Executive...
CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying,...
Exclusive license from Helmholtz Munich will enable ITM to access IP and know-how to develop and commercialize ITM-31 for glioblastoma...
WARREN, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of...
The PMDA enters 9th consecutive year of using Certara’s softwarePRINCETON, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Certara, Inc., (Nasdaq:...